Novo CEO on M&A: Let's see where the gaps are

Novo Nordisk CEO Mike Doustdar said the drugmaker is evaluating M&A opportunities as competition intensifies. He also discussed operating performance in China and North America, but no financial figures, transaction details, or outlook revisions were disclosed. The comments signal strategic optionality rather than an imminent deal or material change in fundamentals.